Takeda ( TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily ...
The nonprofit Association of Migraine Disorders is reshaping public understanding of migraine through its global Shades For Migraine campaign. Designed to smash ...
A new study suggests that reproducing a crucial sleep-like brain pattern in awake animals may help preserve memory and ...
For millions of people, cannabis has become the unofficial prescription for lost sleep. But what feels like a solution may be ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Ayanna Redwood-Crawford Ayanna Redwood-Crawford is a writer covering beauty ...